Načítá se...

A case of pembrolizumab-induced severe DKA and hypothyroidism in a patient with metastatic melanoma

Immune checkpoint inhibitors (ICIs) have revolutionised cancer therapy and improved outcomes for patients with advanced disease. Pembrolizumab, a monoclonal antibody that acts as a programmed cell death 1 (PD-1(PDCD1)) inhibitor, has been approved for the treatment of advanced melanoma and other sol...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Endocrinol Diabetes Metab Case Rep
Hlavní autoři: Hakami, Osamah A, Ioana, Julia, Ahmad, Shahzad, Tun, Tommy Kyaw, Sreenan, Seamus, McDermott, John H
Médium: Artigo
Jazyk:Inglês
Vydáno: Bioscientifica Ltd 2019
Témata:
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6432978/
https://ncbi.nlm.nih.gov/pubmed/30836329
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1530/EDM-18-0153
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!